Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fadraciclib and Venetoclax in R/R AML or MDS
NCT04017546Phase 1Completed
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Aug 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fadraciclib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoint: Maximum Tolerated Dose. Started Aug 2019; status: completed.
02
Drugs
fadraciclib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04017546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04017546.